<DOC>
	<DOCNO>NCT00578448</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety belatacept de novo renal transplant subject treat belatacept-based immunosuppressant medication</brief_summary>
	<brief_title>Belatacept Pharmacokinetic Trial Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Recipient living decease donor kidney First second transplant Men woman , include woman childbearing potential , 18 year old Panel reactive antibody â‰¥ 30 % Significant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>